RxDoctor Payments Data

Francis Tan, MD

Family Medicine · Las Vegas, NVNPI 1457472490

Payments from drug & device makers

$1,031in general payments, 2019–2025

Across 53 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$180
  • Neurocrine Biosciences, Inc.$152
  • Novo Nordisk$151
  • QOL Medical, LLC$126
  • Amgen$110
  • Amarin Pharma, Inc.$62
  • plus $251 from 8 others

What the payments were for

  • Food & beverage$1,02599%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca7$180
Neurocrine Biosciences, Inc.1$152
Novo Nordisk10$151
QOL Medical, LLC9$126
Amgen5$110
Amarin Pharma, Inc.4$62
Boehringer Ingelheim3$45
Pfizer3$44
Jazz Pharmaceuticals Inc.2$40
Zyla Life Sciences, Inc.2$29
Merck2$28
AbbVie2$27
Johnson & Johnson2$25
Metuchen Pharmaceuticals1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,031 in reported general payments places this provider in the 70th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$254,246
Medicare patients
636
Services billed
2,097

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega HafyeraPaliperidone Palmitate34$730,658
Invega TrinzaPaliperidone Palmitate15$160,335
EliquisApixaban128$34,244
XareltoRivaroxaban91$24,642
Sevelamer Hcl18$6,774
DuleraMometasone/Formoterol11$3,933
Sucralfate39$3,400
Divalproex Sodium98$2,866
Atorvastatin Calcium300$2,837
Lantus SolostarInsulin Glargine,hum.Rec.Anlog54$2,530
Gabapentin167$2,407
Breo ElliptaFluticasone/Vilanterol11$1,825
Midodrine Hcl22$1,766
Memantine Hcl73$1,572
Sevelamer Carbonate13$1,493

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Xarelto$25$184,977106 claims
PfizerEliquis$44$34,244128 claims
MerckDulera$28$3,93311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 902 family medicine providers in Nevada.

Other family medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →